Wealthcreatures.com

Deepak Nitrite Sleeping 😴 Lion 🦁 Getting Ready for Wake up soon 🔜 in next 6-9 -12 months or even before Capex coming into play in 6-9 -12 months Support @ 1330-1400 CMP - 1550

WOCKHARDT PHARMA From Turnaround to Innovation Story Hockey Stick Growth Key Highlights from FY26 Results + Investor Meet + Concall: ✅ Revenue: ₹3,373 Cr ✅ EBITDA: ₹630 Cr (+51%) ✅ PAT Turnaround: Loss → ₹213 Cr Profit ✅ Net Debt/Equity: Just 0.10 ✅ Operating Cash Flow: ₹390 Cr 💊 ZAYNICH – The Game Changer • First Indian-discovered antibiotic approved by US FDA • Targets highly drug-resistant Gram-negative infections • US market opportunity: 1.2 million hospital infections annually • Global revenue opportunity estimated at $1.5–2 Billion 📈 Management's Most Important Comment: "Hockey Stick Growth" FY27: ➡️ Hospital onboarding ➡️ Formulary approvals ➡️ Initial adoption FY28: ➡️ Wider physician acceptance ➡️ Revenue acceleration FY29 onwards: ➡️ Potential hockey-stick growth curve 🌍 Additional Growth Drivers • UK subscription model up to £20M annually • Emrok & Miqnaf scaling in India • Diabetes biosimilars pipeline • Odrate & future antibiotic portfolio 📊 Technical Setup • Retesting major breakout zone ₹1,870–1,900 • 12-year resistance zone around ₹2,000–2,050 • Successful breakout above this zone can change the long-term valuation narrative 💡 Market is no longer valuing Wockhardt as a generic pharma company. The next 4–6 quarters will depend on: ✔️ Zaynich US sales ✔️ Hospital penetration ✔️ Formulary approvals ✔️ Adoption curve If management delivers the promised "hockey-stick" trajectory, FY30 could look very different from FY26.

Sakar Healthcare Business Profile - India's only NSE-listed, API-backward-integrated oncology formulations exporter - Operates two EU-GMP approved manufacturing facilities - Changodar plant: Oral solids, injectables and DPI products - Bavla plant: Oncology and cytotoxic formulations - Business mix includes oncology formulations and non-oncology/CDMO operations CDMO & Customer Base - Works with leading pharma companies including Zydus, Emcure, Glenmark, Cipla, Abbott and Ipca - CDMO and non-oncology business supports capacity utilization - Provides operational stability while oncology business scales FY26 Performance - Revenue: ₹251.7 Cr (+42% YoY) - EBITDA: ₹68.9 Cr - EBITDA Margin: 27.4% - PAT: ₹30.5 Cr (+74% YoY) Oncology Business Scaling Up - Q4 FY26 oncology revenue: ₹31.5 Cr (+230% YoY) - Oncology contributed 46% of Q4 FY26 revenue - Domestic oncology business has reached ~₹95 Cr run-rate - Supported by 40 supply agreements - 125+ dossiers filed - 12 marketing authorisations Key Growth Trigger – Export Oncology - Export oncology revenue currently remains negligible - Management aims to build export oncology business to ~₹95 Cr by FY27 - Potential to match domestic oncology revenues - Represents the most important growth lever for the company Capacity Advantage - Existing manufacturing infrastructure can support ~₹1,000 Cr revenue - Current utilization around 30% - Significant operating leverage available - No major incremental capex required for near-term growth Regulatory & Product Pipeline - Secured 5 international approvals - 3 EMA approvals - 2 MHRA approvals - 31 own-dossier registrations under process - Management expects ~80% conversion into commercial supplies by Q3 FY27 Accord-Intas Partnership - Technology transfer agreement signed - Portfolio includes 10 products across 9 molecules - Estimated opportunity of ₹50–100 Cr - Only 2 molecules commercialized so far - Significant potential remains untapped Backward Integration - 21 in-house cytotoxic APIs - 2 APIs have CEP approvals - 5 additional CEP approvals targeted - Expected to reduce cost of goods over time - Supports long-term margin expansion Margin Outlook - Long-term EBITDA margin target around 30% - Backward integration expected to improve profitability - Export scale-up can drive significant operating leverage Growth Outlook - Domestic oncology continues to scale strongly - Export oncology expected to become the next growth engine - Existing capacity provides room for multiple years of growth - Commercialization of approved dossiers remains the key catalyst Key Monitorables - Export oncology revenue ramp-up - EMA and MHRA site-variation approvals in Q2 FY27 - Conversion of 31 filed dossiers into commercial supplies - Commercialization of remaining Accord-Intas molecules - Capacity utilization improvement Key Risks - Export oncology ramp-up slower than expected - Approval delays - Execution risk in international markets - Data consistency concerns around approval and dossier disclosures - Rich valuation leaves limited room for operational slippage Valuation Consideration - Trading at around 60x trailing earnings - Current valuation assumes successful execution of export ramp-up - Future returns highly dependent on converting regulatory approvals into commercial sales Impact - Positive, but execution-sensitive - Domestic oncology business has already demonstrated strong traction - Export oncology remains the critical catalyst that can unlock the next phase of growth - Existing underutilized capacity and backward integration create significant operating leverage if management delivers on commercialization targets

Just a Recall March 2026 Nifty Lows - 22331 War has ended Hopefully And March was Best month even to add many good stocks—-> from March lows many Stocks have surged and given good Rally

Just an Observation 🔸China is becoming "uninvestable" due to geopolitical risks and uncertainty around capital exits. 🔸Taiwan is a TSMC story. 🔸South Korea is a Samsung and SK Hynix story. 🔸Brazil is a Vale and Petrobras story. 🔸India has growth drivers across consumption, manufacturing, financials, healthcare, technology, infrastructure and more industry 🔸India may not be the cheapest market when compared to world 🌍 markets But it is one of the few economies with the potential to double and then double again in next few years Think about it

Azad Engineering 2222 Getting Ready for ATH 🔜

Wockhardt pharma @1852 Opportunity if have patience

Deepak Fertlizer 1550

Deepak Fertlizer 1475 Watch out for close above 1480-1510 zone For next Upmove

sterlite Tech Days Low @ 567

Nifty Days Low @ 23070 Nifty Support @ 23000 22740-22775 zome should not be Tested If Tested more downside can open Let’s c

On Radar Motilal oswal fund has bought one More stock worth 225cr recently around 619 zone only Mutual funds look at forward PE - Retailers must also look at too same way Stock has already went from 75 To 619 Stock name - Sterlite Tech

Azad Engineering 5% 💚 2200

Wockhardt pharma 9% 💣 2150 Range for next few days 2000 - 2360

Textile sector 2 stocks Sportking Sarla poly

Wockhardt pharma The fall & Shakeout of Weakhands happening & Retesting last Resistance now shld act as support Let’s C Yesterday High - 2422 Today Available @ 1960 at Days Low 💪 support @ 1900-1965 zone

Azad Engineering Days Low @ 1951 Let’s c where it making bottom in current drag down